Skip to content

Health Professional Exposure Assessment to Covid-19

Health Professional Exposure Assessment to Covid-19

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04429724
Acronym
SERODRON
Enrollment
2129
Registered
2020-06-12
Start date
2020-07-06
Completion date
2021-03-16
Last updated
2022-05-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Brief summary

Understanding the SARS-Cov2 epidemic is a major public health issue, both in the community and in the hospital sector. Because of their central position in the management of patients infected with COVID-19, hospital staff may be considered at high risk of infection. The development of serological tests makes it possible to reliably document a contamination, symptomatic or not, that is more than 3 weeks old. These tests, combined with clinical questioning of the symptoms, make it possible to determine the proportion of asymptomatic infections whose impact in the transmission of this disease appears to be major. The duration of the presence of the antibodies that are hoped to neutralize after infection with CoV2-SARS remains uncertain. Documenting the evolution of antibody levels and their monitoring in a population at high risk of re-exposure to CoV2-SARS is a major issue in understanding this disease and in assessing the risk of infection among healthcare workers.

Detailed description

This is a multi-center, prospective, interventional, low-risk, low-constraint, biological collection study to assess the exposure of health care workers to COVID-19. Three blood samples will be taken at day 1, month 3 and month 6. The blood samples will be stored in a serum biological collection. A prospective data collection will be set up at the level of symptoms and co-morbidities at each collection at D1, M3 and M6. In the event of the appearance of symptoms between samples, a self-questionnaire will be completed by the participating personnel as well as an invitation to screening by RT-PCR SARS Cov2 according to standard practices in force at the national level as well as an additional serological test.

Interventions

DIAGNOSTIC_TESTDiagnostic test Covid-19

Three blood samples will be taken at day 1, month 3 and month 6 A prospective data collection will be set up at the level of symptoms and co-morbidities at each collection at D1, M3 and M6.

Sponsors

Tourcoing Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Staff on duty in the health facility * Eligible to be drawn * Beneficiary subject affiliated or entitled to a social security scheme

Exclusion criteria

* Minor patient * Refusal to participate * Patient under guardianship * Patient under guardianship

Design outcomes

Primary

MeasureTime frameDescription
Number of contaminated personnelday 1Number of contaminated personnel by occupational category and department on day 1.

Secondary

MeasureTime frameDescription
Number of contaminated personnelmonth 3Number of contaminated personnel by professional category and by service at month 3 a by serological test
Number of symptomatic staff by occupational category and servicemonth 3Number of symptomatic staff by occupational category and service at Month 3 with positive RT-PCR Cov2 SARS
Number of contaminated personnel with effective protectionevolution at day 1, month 3 and month 6Number of contaminated personnel with effective protection: evolution of the antibody index at day 1, month 3 and month 6
comparison of socio-demographic characteristics and co-morbidities between patients losing their antibodies and those maintaining their antibodiesmonth 6comparison of socio-demographic characteristics and co-morbidities between patients losing their antibodies and those maintaining their antibodies between two stitch dates.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026